Clinical Trial Update: Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update comparing once-daily elvucitabine to lamivudine in participants with an M184V mutation in HIV infections; completed phase 1/2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Elvucitabine (elvucitabine)
• Lamivudine (lamivudine)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED